Cancer & SURVIVEiT News

The SURVIVEiT® NewsRoom provides patients with quick access to exclusive news, treatment breakthroughs, survivor stories, and expert interviews providing the latest insight about this rapidly evolving industry. Visit our NewsRoom often and follow us on Facebook.

SURVIVEiT_Progress_Newsroom_2020

Head & Neck: “Study finds combined therapy improves cancer patient results”

 Study finds combined therapy improves cancer patient results SIOUX FALLS, S.D., Aug. 11, 2020 — Sanford Health, the largest provider of rural health care in the country, today announced the findings...
SURVIVEiT_Cancer_Survivor_QA___Where_do_you_find_hope,_inspiration_and_strength_

Cancer Survivor Q&A | Where Do You Find Hope, Inspiration & Strength?

SURVIVEiT®’s Survivor Advisory Council & Committee is made up of cancer survivors who have travelled the path and understand the journey in a way others cannot. Their wisdom is what...
FDA_Drug_Newsroom

FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma

FDA approves atezolizumab for BRAF V600 unresectable or metastatic melanoma On July 30, 2020, the Food and Drug Administration approved atezolizumab (Tecentriq, Genentech, Inc.) in combination with cobimetinib and vemurafenib...
Blog_Header_Template_-_Navigating_Now_Second_Opinions

Navigating Second Opinions: You Have The Most At Stake | Navigating Now

I’ve worked hard all my life. I saved up enough money to pay cash for my brand-new BMW. A month after I buy it, the check engine light comes on....
CRISPR_news

How CRISPR Is Changing Cancer Research and Treatment

How CRISPR Is Changing Cancer Research and Treatment The new tool has taken the research world by storm, markedly shifting the line between possible and impossible. As soon as CRISPR...
SURVIVEiT_SURVIVEiT®_LAUNCHES_INDIEGOGO_CAMPAIGN_TO_HELP_PATIENTS_NAVIGATE_CANCER_JOURNEY_Blog_Image

News Release: SURVIVEiT® Launches Indiegogo Campaign To Help Patients Navigate Cancer Journey

4600 People Each Day are Diagnosed with Cancer and Seek Information Online to Assist Them on Their Cancer Journey (New York, NY, July 21, 2020) - SURVIVEiT has launched an...
SURVIVEiT_Cancer_COPilOT_Blog_Image

SURVIVEiT®’s Cancer Navigation Tool | Back Our Crowdfunding Campaign Today

It has been our mission to design a tool that will change the experience of a cancer diagnosis for all patients. Today we are announcing that we’ve done it, and...
SURVIVEiT_Cancer_Survivor_QA___What_is_the_best_way_to_support_someone_who_has_just_been_diagnosed_with_cancer_

Cancer Survivor Q&A | The Best Way To Support Someone Who Has Been Diagnosed With Cancer

SURVIVEiT®’s Survivor Advisory Council & Committee is made up of cancer survivors who have travelled the path and understand the journey in a way others cannot. Their wisdom is what...
SURVIVEiTSarcoma_Survivor_Story___Desmoplastic_Small_Round_Cell_Tumor

Sarcoma Survivor Story | Desmoplastic Small Round Cell Tumor

The following sarcoma survivor story is about Carl Cranum, a college athlete who was diagnosed with a desmoplastic small round cell tumor. Read the story of his sarcoma diagnosis and...
covid_immunotherapy_image

Cancer Immunotherapy Tied to Severe COVID-19 Outcomes

Cancer Immunotherapy Tied to Severe COVID-19 Outcomes Cancer patients receiving immunotherapy were at increased risk for severe outcomes from COVID-19, according to retrospective findings from Memorial Sloan Kettering Cancer Center...
FDA_Drug_Newsroom

FDA approves avelumab for urothelial carcinoma maintenance treatment

FDA approves avelumab for urothelial carcinoma maintenance treatment On June 30, 2020, the Food and Drug Administration approved avelumab (BAVENCIO,EMD Serono, Inc.) for maintenance treatment of patients with locally advanced...
FDA_Drug_Newsroom

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast

FDA approves combination of pertuzumab, trastuzumab, and hyaluronidase-zzxf for HER2-positive breast cancer On June 29, 2020, the Food and Drug Administration approved a new fixed-dose combination of pertuzumab, trastuzumab, and...